updates searched

L7 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Heterocyclyl (thio)carbamate and (thio)urea derivs. represented by general formula [I; R = (un)substituted aryl; R1 = cycloalkyl, (un)substituted aryl; R2 = H, OH, lower alkyl, lower alkoxy, cycloalkyl, aryl; R3 = H, lower alkyl; X = O, S; Y = O, S, (un)substituted NH, CH2, OCH2; ring A = heterocyclyl Q - Q1; wherein m, n = 1-4, provided that m + n = 3-5; l = 1-3, provided that m + l = 3-5; p, q = 0, 1; r, s, t = 0-3, provided that r + s + t = 2 or 3; Z = N(O)qR4, N+R5R6.Q-; Z1 = N(O)q, N+R6.Q-; wherein Q- = anion; R4 = H, lower alkyl, alkenyl, or alkynyl, B-R7; R5 = lower alkyl, alkenyl, or alkynyl, B-R7; R6 = lower alkyl, alkenyl, or alkynyl; wherein R7 = cycloalkyl, lower (hydroxy)alkoxy, benzhydryl, (un)substituted aryl, optionally benzene ring-fused or (un)substituted heterocyclyl containing 1 or 2 heteroatoms; B = single bond, lower alkylene, alkenylene, or alkynylene] or salts, hydrates or solvates thereof are prepared A muscarine M3 receptor antagonist for preventing or treating digestive tract, respiratory or urol. diseases such as irritable bowel syndrome, spasmodic colitis, diverticulitis, chronic obstructive lung diseases, chronic bronchitis, asthma, rhinitis, neural pollakiurea, nocturnal enuresis, nervous bladder, unstable bladder, bladder contracture, chronic cystitis, urinary incontinence, and pollakiurea, contains the said compound I. Thus, 2.92 g NaBH(OAc)3 was added portion-wise to a solution of 1.60 g 4-piperidyl N-benzhydrylcarbamate hydrochloride (preparation given) and 0.40 mL 3-thiophenecarbaldehyde in 20 mL ClCH2CH2Cl and the resulting mixture was stirred at room temperature overnight to give, after silica gel chromatog. and salt formation, a title compound [II.(CO2H)2]. II.(CO2H)2 in vitro showed binding affinity to muscarine M1 receptor of cerebral cortex, muscarine M2 receptor of heart, and muscarine M3 receptor of submaxillary gland with Ki value of 1.0, 350, and 6.0 nM, resp., and Ki(M2 receptor)/Ki (M3 receptor) ratio of 58.
AN 1995:849168 CAPLUS
DN 123:285789
TI Preparation of heterocyclyl carbamate derivatives with muscarine M3 receptor antagonism
IN Takeuchi, Makoto; Naito, Ryo; Morihira, Koichiro; Hayakawa, Masahiko; Ikeda, Ken; Isomura, Yasuo; Tomioka, Kenichi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9506635	A1	19950309	WO 1994-JP1436		19940831
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				JP 1993-218620	A	19930902
				JP 1994-77575	A	19940415
	AU 9475458	A1	19950322	AU 1994-75458		19940831
				JP 1993-218620	A	19930902
				JP 1994-77575	A	19940415
				WO 1994-JP1436	W	19940831

OS MARPAT 123:285789
IT **168830-01-1P 168830-81-7P 168830-82-8P**
168830-86-2P 168830-88-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of heterocyclyl (thio)carbamate derivs. as muscarine M3 receptor antagonists)
RN 168830-01-1 CAPLUS
CN Carbamic acid, (diphenylmethyl)-, 1-[(3-aminophenyl)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 168830-81-7 CAPLUS
CN Propanamide, N-(diphenylmethyl)-3-[[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 168830-82-8 CAPLUS
CN Propanamide, N-(diphenylmethyl)-3-[[1-(phenylmethyl)-4-piperidinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 168830-86-2 CAPLUS
CN Carbamic acid, (diphenylmethyl)-, 1-[[4-[[(trifluoroacetyl)amino]methyl]phenyl]methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 168830-88-4 CAPLUS

CN Carbamic acid, [4-[[4-[[[(diphenylmethyl)amino]carbonyl]oxy]-1-piperidinyl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **168829-04-7P 168829-08-1P 168829-09-2P**
168829-14-9P 168829-17-2P 168829-18-3P
168829-20-7P 168829-23-0P 168829-24-1P
168829-26-3P 168829-27-4P 168829-28-5P
168829-29-6P 168829-30-9P 168829-31-0P
168829-32-1P 168829-33-2P 168829-34-3P
168829-35-4P 168829-36-5P 168829-41-2P
168829-45-6P 168829-51-4P 168829-52-5P
168829-54-7P 168829-56-9P 168829-57-0P
168829-58-1P 168829-61-6P 168829-63-8P
168829-65-0P 168829-67-2P 168829-73-0P
168829-75-2P 168829-77-4P 168829-79-6P
168829-81-0P 168829-83-2P 168829-86-5P
168829-88-7P 168829-89-8P 168829-90-1P
168829-91-2P 168829-92-3P 168829-93-4P
168829-94-5P 168829-96-7P 168829-97-8P
168829-98-9P 168829-99-0P 168830-00-0P
168830-01-1P 168830-02-2P 168830-10-2P
168830-14-6P 168830-15-7P 168830-17-9P
168830-18-0P 168830-36-2P 168830-43-1P
168830-44-2P 168830-50-0P 168830-62-4P
168830-63-5P 168830-64-6P 168830-65-7P
168830-66-8P 168830-71-5P 168830-73-7P
168830-74-8P 168830-75-9P 168830-77-1P
168830-80-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl (thio)carbamate derivs. as muscarine M3 receptor antagonists)

RN 168829-04-7 CAPLUS
CN Carbamic acid, (diphenylmethyl)-, 1-(phenylmethyl)-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 168829-08-1 CAPLUS
CN Carbamic acid, (diphenylmethyl)-, 1-(phenylmethyl)-3-piperidinyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 168829-07-0
CMF C26 H28 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 168829-09-2 CAPLUS
CN Carbamic acid, (1,1-diphenylethyl)-, 1-(phenylmethyl)-4-piperidinyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 168829-14-9 CAPLUS
CN Carbamic acid, (triphenylmethyl)-, 1-(phenylmethyl)-4-piperidinyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO0-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorenecarboxamide (preparation given) was alkylated by I(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

AN 1996:641305 CAPLUS
DN 125:275663
TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626205	A1	19960829	WO 1996-US824	19960201

W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
CA 2091102	AA	19930907	CA 1993-2091102	19930305
			US 1992-847503	A 19920306
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
			US 1992-847503	A 19920306
JP 06038761	A2	19940215	JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

			US 1992-847503	A 19920306
AT 219514	E	20020715	AT 1993-103697	19930308
			US 1992-847503	A 19920306
PT 584446	T	20020930	PT 1993-103697	19930308
			US 1992-847503	A 19920306
ES 2178640	T3	20030101	ES 1993-103697	19930308
			US 1992-847503	A 19920306
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
			US 1992-847503	A 19920306
US 5739135	A	19980414	US 1995-472067	19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
AU 9647631	A1	19960911	AU 1996-47631	19960201
AU 699865	B2	19981217		
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
EP 886637	A1	19981230	EP 1996-903604	19960201
EP 886637	B1	20041201		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
JP 11500442	T2	19990112	JP 1996-525679	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
AT 283851	E	20041215	AT 1996-903604	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220
			US 1995-391901	A 19950221

FI 9703416	A	19970820	FI 1997-3416		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
NO 9703821	A	19970820	NO 1997-3821		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
LT 4367	B	19980825	LT 1997-152		19970919
			US 1995-391901	A	19950221

PATENT FAMILY INFORMATION:

FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	EP 643057	A1	19950315	EP 1994-113800		19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
				US 1993-117362	A	19930903
	CA 2091102	AA	19930907	CA 1993-2091102		19930305
				US 1992-847503	A	19920306
	ZA 9301601	A	19931005	ZA 1993-1601		19930305
				US 1993-117362	A	19930903
	HU 67962	A2	19950529	HU 1993-627		19930305
	HU 218419	B	20000828			
				US 1992-847503	A	19920306
	JP 06038761	A2	19940215	JP 1993-46499		19930308
				US 1992-847503	A	19920306
	EP 584446	A2	19940302	EP 1993-103697		19930308
	EP 584446	A3	19950426			
	EP 584446	B1	20020619			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
				US 1992-847503	A	19920306
	AT 219514	E	20020715	AT 1993-103697		19930308
				US 1992-847503	A	19920306
	PT 584446	T	20020930	PT 1993-103697		19930308
				US 1992-847503	A	19920306
	ES 2178640	T3	20030101	ES 1993-103697		19930308
				US 1992-847503	A	19920306
	AU 670930	B2	19960808	AU 1993-34064		19930309
	AU 9334064	A1	19930909			
				US 1992-847503	A	19920306
	US 5595872	A	19970121	US 1993-117362		19930903
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
	CA 2131430	AA	19950304	CA 1994-2131430		19940902
				US 1993-117362	A	19930903
	FI 9404048	A	19950304	FI 1994-4048		19940902
				US 1993-117362	A	19930903
	NO 9403260	A	19950306	NO 1994-3260		19940902
				US 1993-117362	A	19930903
	AU 9471642	A1	19950316	AU 1994-71642		19940902
	AU 690125	B2	19980423			
				US 1993-117362	A	19930903
	ZA 9406772	A	19950403	ZA 1994-6772		19940902
				US 1993-117362	A	19930903
	JP 07165712	A2	19950627	JP 1994-210057		19940902
				US 1993-117362	A	19930903
	CN 1106003	A	19950802	CN 1994-115640		19940902
				US 1993-117362	A	19930903
	HU 70613	A2	19951030	HU 1994-2542		19940902

				US 1993-117362	A	19930903
	US 5789197	A	19980804	US 1995-486924		19950607
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
	US 6492365	B1	20021210	US 1995-486929		19950607
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
	US 2003166590	A1	20030904	US 2001-933593		20010821
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
				US 1995-486929	A3	19950607

FAN 1998:115356

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5712279	A	19980127	US 1996-548811		19960111
				US 1995-391901	B2	19950221
				US 1995-472067	A2	19950606
	CA 2091102	AA	19930907	CA 1993-2091102		19930305
				US 1992-847503	A	19920306
	HU 67962	A2	19950529	HU 1993-627		19930305
	HU 218419	B	20000828			
				US 1992-847503	A	19920306
	JP 06038761	A2	19940215	JP 1993-46499		19930308
				US 1992-847503	A	19920306
	EP 584446	A2	19940302	EP 1993-103697		19930308
	EP 584446	A3	19950426			
	EP 584446	B1	20020619			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
				US 1992-847503	A	19920306
	AT 219514	E	20020715	AT 1993-103697		19930308
				US 1992-847503	A	19920306
	PT 584446	T	20020930	PT 1993-103697		19930308
				US 1992-847503	A	19920306
	ES 2178640	T3	20030101	ES 1993-103697		19930308
				US 1992-847503	A	19920306
	AU 670930	B2	19960808	AU 1993-34064		19930309
	AU 9334064	A1	19930909			
				US 1992-847503	A	19920306
	US 5739135	A	19980414	US 1995-472067		19950606
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
	ZA 9601340	A	19970911	ZA 1996-1340		19960220
				US 1995-391901	A	19950221
	LT 4367	B	19980825	LT 1997-152		19970919
				US 1995-391901	A	19950221

FAN 1998:236274

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5739135	A	19980414	US 1995-472067		19950606
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
	CA 2091102	AA	19930907	CA 1993-2091102		19930305
				US 1992-847503	A	19920306
	HU 67962	A2	19950529	HU 1993-627		19930305

HU 218419	B	20000828				
			US 1992-847503	A	19920306	
JP 06038761	A2	19940215	JP 1993-46499		19930308	
			US 1992-847503	A	19920306	
EP 584446	A2	19940302	EP 1993-103697		19930308	
EP 584446	A3	19950426				
EP 584446	B1	20020619				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE						
			US 1992-847503	A	19920306	
AT 219514	E	20020715	AT 1993-103697		19930308	
			US 1992-847503	A	19920306	
PT 584446	T	20020930	PT 1993-103697		19930308	
			US 1992-847503	A	19920306	
ES 2178640	T3	20030101	ES 1993-103697		19930308	
			US 1992-847503	A	19920306	
AU 670930	B2	19960808	AU 1993-34064		19930309	
AU 9334064	A1	19930909				
			US 1992-847503	A	19920306	
US 5595872	A	19970121	US 1993-117362		19930903	
			US 1992-847503	B2	19920306	
			US 1993-15449	B2	19930222	
US 5789197	A	19980804	US 1995-486924		19950607	
			US 1992-847503	B2	19920306	
			US 1993-15449	B2	19930222	
			US 1993-117362	A3	19930903	
US 6492365	B1	20021210	US 1995-486929		19950607	
			US 1992-847503	B2	19920306	
			US 1993-15449	B2	19930222	
			US 1993-117362	A3	19930903	
US 5712279	A	19980127	US 1996-548811		19960111	
			US 1995-391901	B2	19950221	
			US 1995-472067	A2	19950606	
IL 116917	A1	20000831	IL 1996-116917		19960126	
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
TW 486469	B	20020511	TW 1996-85100978		19960126	
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
CA 2213466	AA	19960829	CA 1996-2213466		19960201	
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
WO 9626205	A1	19960829	WO 1996-US824		19960201	
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
AU 9647631	A1	19960911	AU 1996-47631		19960201	
AU 699865	B2	19981217				
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
			WO 1996-US824	W	19960201	
CN 1176640	A	19980318	CN 1996-192015		19960201	
CN 1108301	B	20030514				
			US 1995-391901	A	19950221	
			US 1995-472067	A	19950606	
EP 886637	A1	19981230	EP 1996-903604		19960201	
EP 886637	B1	20041201				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE						

			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
JP 11500442	T2	19990112	JP 1996-525679		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
NZ 302055	A	20000228	NZ 1996-302055		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
PL 185443	B1	20030530	PL 1996-322003		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
AT 283851	E	20041215	AT 1996-903604		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
ES 2233961	T3	20050616	ES 1996-903604		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
ZA 9601340	A	19970911	ZA 1996-1340		19960220
			US 1995-391901	A	19950221
US 5883099	A	19990316	US 1997-896872		19970721
			US 1993-117362	A2	19930903
			US 1994-284808	B2	19940805
			US 1995-391901	B2	19950221
			US 1995-472067	A3	19950606
US 6034098	A	20000307	US 1997-898304		19970721
			US 1993-117362	A2	19930903
			US 1994-284808	B2	19940805
			US 1995-391901	B2	19950221
			US 1995-472067	A3	19950606
US 6066650	A	20000523	US 1997-898303		19970721
			US 1993-117362	A2	19930903
			US 1994-284808	B2	19940805
			US 1995-391901	B2	19950221
			US 1995-472067	A1	19950606
FI 9703416	A	19970820	FI 1997-3416		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
NO 9703821	A	19970820	NO 1997-3821		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
LT 4367	B	19980825	LT 1997-152		19970919
			US 1995-391901	A	19950221
LV 11951	B	19981120	LV 1997-171		19970919
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
US 2003166590	A1	20030904	US 2001-933593		20010821
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
			US 1993-117362	A3	19930903
			US 1995-486929	A3	19950607

OS MARPAT 125:275663
IT **182432-59-3P 182436-56-2P 182438-01-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 182432-59-3 CAPLUS

CN 1,2-Benzenedicarboxamide, N-(diphenylmethyl)-N'-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182436-56-2 CAPLUS

CN 1,2-Benzenedicarboxamide, N-(diphenylmethyl)-N'-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182438-01-3 CAPLUS
CN 1,2-Benzenedicarboxamide, N-(diphenylmethyl)-N'-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

AB The replacement of the benzhydrylic oxygen atom of our previously developed dopamine transporter (DAT)-specific ligands 4-[2-(diphenylmethoxy)ethyl]-1-[(4-fluorophenyl)methyl]piperidine and 4-[2-(bis(4-fluorophenyl)methoxy)ethyl]-1-benzylpiperidine by a nitrogen atom resulted in the development of N-analogs 4-[2-((diphenylmethyl)amino)ethyl]-1-[(4-fluorophenyl)methyl]piperidine and 4-[2-((bis(4-fluorophenyl)methyl)amino)ethyl]-1-benzylpiperidine. Biol. evaluation of these compds. in rat striatal tissue and in HEK-293 cells expressing the cloned human transporters demonstrated high potency and selectivity of these compds. for the DAT. Thus the potency of 4-[2-((diphenylmethyl)amino)ethyl]-1-[(4-fluorophenyl)methyl]piperidine for the DAT was 9.4 and 30 nM in rat striatal tissue and in the cloned transporter cells, and its binding selectivity for the DAT compared to the serotonin transporter (SERT) for these two systems was 62 and 195, resp. Similarly, 4-[2-((bis(4-fluorophenyl)methyl)amino)ethyl]-1-benzylpiperidine exhibited high potency and selectivity for the DAT. Thus, the replacement of the O atom in the parent compds. only had small effects on potency and selectivity. In comparison with GBR 12909 [1-[2-(bis(4-fluorophenyl)methoxy)ethyl]-4-(3-phenylpropyl)piperazine] and WIN 35,428 [3β-(p-fluorophenyl)-2β-carbomethoxytropane] binding, these two novel N-analogs were slightly more potent and far more selective for the DAT. Thus, these novel N-analogs represent more polar new-generation piperidine congeners of GBR 12909. They might have useful potential application in developing a pharmacotherapy for cocaine dependence.

AN 1998:505470 CAPLUS
DN 129:175524

TI Tolerance in the Replacement of the Benzhydrylic O Atom in 4-[2-(Diphenylmethoxy)ethyl]-1-benzylpiperidine Derivatives by an N Atom: Development of New-Generation Potent and Selective N-Analog Molecules for the Dopamine Transporter

AU Dutta, Aloke K.; Xu, Cen; Reith, Maarten E. A.
CS Organix Inc., Woburn, MA, 01801, USA

SO Journal of Medicinal Chemistry (1998), 41(17), 3293-3297
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

IT **211631-82-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [((phenylmethyl)amino)ethyl][(fluorophenyl)methyl]piperidine derivs. as dopamine transporter ligands)

RN 211631-82-2 CAPLUS
CN 4-Piperidineacetamide, N-[bis(4-fluorophenyl)methyl]-1-(phenylmethyl)-(9CI) (CA INDEX NAME)



IT **211631-81-1P**